• betway altior offer Medical Care with continued strong earnings growth in constant currency
  • betway altior offer Kabi showed a recovery in Europe and return to growth in China whilst headwinds weigh on North American business
  • Helios Germany with sales growth in Q3 due to recovery of elective procedures; Helios Spain with significant growth based on catch-up effects
  • betway altior offer Vamed continues to be heavily impacted by COVID-19 related project delays, high-end technical service remained robust

If no timeframe is specified, information refers to Q3/2020; 2020 and 2019 according to IFRS 16

        1. 1 Before special items
          2 Net income attributable to shareholders of betway altior offer SE & Co. KGaA
          For a detailed overview of special items please see the reconciliation tables on pages 17-19 in the PDF document.

          <p id="jnr1mns8" style="display:none !important"></p><samp id="0t1za8xj" style="display:none !important"><kbd id="xc920vsx" style="display:none !important"></kbd></samp><kbd id="9pcj23oq" style="display:none !important"><table id="7cmsw03n" style="display:none !important"></table><sub id="lje42zb2" style="display:none !important"><h1 id="rmd3hpjg" style="display:none !important"></h1></sub></kbd><h6 id="vfuz7xsk" style="display:none !important"><td id="zwgagc25" style="display:none !important"></td><s id="6dv0n4w3" style="display:none !important"><output id="mv2tvyyy" style="display:none !important"></output></s><address id="vb78nsy6" style="display:none !important"><sub id="q4ijzdd9" style="display:none !important"></sub><colgroup id="nc1bynac" style="display:none !important"><var id="8vbsg27l" style="display:none !important"></var></colgroup></address></h6><pre id="etrr87xy" style="display:none !important"><col id="cvhps1ln" style="display:none !important"></col><ruby id="n1nwx1o5" style="display:none !important"><form id="6i0b3d5e" style="display:none !important"></form></ruby><sup id="wriynv1d" style="display:none !important"><h1 id="0ezrt2a6" style="display:none !important"></h1><img id="xr2m5fqd" style="display:none !important"><figcaption id="39pg90lm" style="display:none !important"></figcaption></img></sup><li id="huswfq2t" style="display:none !important"><h1 id="b2ltatmr" style="display:none !important"></h1></li></pre><table id="vrd589af" style="display:none !important"><ruby id="sv46ut00" style="display:none !important"></ruby><wbr id="1mvfkdaw" style="display:none !important"><code id="j3ui4mz3" style="display:none !important"></code></wbr><area id="5ux2s5h1" style="display:none !important"><menu id="m6nx9jit" style="display:none !important"></menu></area><tt id="xuyu8gju" style="display:none !important"><code id="xq59ypzm" style="display:none !important"></code><figure id="e1oc5t9q" style="display:none !important"><cite id="8uv2cwdo" style="display:none !important"></cite></figure><table id="74fd0qpj" style="display:none !important"><var id="43fr62hg" style="display:none !important"></var><param id="we9oefl5" style="display:none !important"><acronym id="y59t5p4k" style="display:none !important"></acronym></param></table></tt><q id="4n7k5rn9" style="display:none !important"><menu id="k1ljlav0" style="display:none !important"></menu><big id="5h70wlz8" style="display:none !important"><embed id="3sors2al" style="display:none !important"></embed></big><thead id="b4qywbc9" style="display:none !important"><legend id="e4jyaghy" style="display:none !important"></legend></thead><commend id="85xgu48t" style="display:none !important"><area id="gpe0up9a" style="display:none !important"></area><del id="5fm556ye" style="display:none !important"><samp id="10s81cwt" style="display:none !important"></samp></del><tt id="vjw15y17" style="display:none !important"><dir id="wlkwjr56" style="display:none !important"></dir><label id="lpzsuv1m" style="display:none !important"><figcaption id="8u6pl3z9" style="display:none !important"></figcaption></label></tt></commend></q></table><meter id="xs10c65n" style="display:none !important"><ul id="f6glr783" style="display:none !important"></ul></meter>

        2.  

          <source id="guj4e749" style="display:none !important"></source>
          1. <td id="t2im0snj" style="display:none !important"></td>

              <h1 id="jik5dbja" style="display:none !important"></h1><del id="57q5itoy" style="display:none !important"><output id="9fwpjfp7" style="display:none !important"></output></del><dd id="p3u28o2z" style="display:none !important"><u id="oa5aabuj" style="display:none !important"></u><style id="16q3hgf9" style="display:none !important"><output id="gtvjr597" style="display:none !important"></output></style></dd><source id="2s6t0s8q" style="display:none !important"><thead id="bmgpb9uf" style="display:none !important"></thead></source><form id="mrqve33h" style="display:none !important"><legend id="vofmyw3j" style="display:none !important"></legend></form>

              Stephan Sturm, CEO of betway altior offer, said: "betway altior offer remains stable and resilient, and was able to show it once again in the third quarter. Despite the ongoing and in some cases drastic restrictions caused by COVID-19, our patients could continue to rely on and benefit from our care. betway altior offer is also reliable, in terms of business development: We forecasted that after a second quarter impacted by the lockdowns our sales and earnings would resume their positive trajectory – and they did just that. Despite the coronavirus, we were even able to achieve a strong increase in sales over last year’s third quarter. Our quarterly earnings of €427 million are also robust. We are well prepared for the challenges that the pandemic will pose to us over the coming months. As a result, I remain confident that we will reach our 2020 targets and continue our healthy growth in the coming years."
               

                      FY/20 Group guidance
                      Based on the Group’s solid business development in Q1-3/20, betway altior offer confirms its sales and net income guidance for 2020 including estimated COVID-19 effects. betway altior offer projects sales growth1 of 3% to 6% in constant currency. Net income2,3 is expected to develop in a range of - 4% to +1%.

                          betway altior offer projects net debt/EBITDA4 to be around the top-end of the self-imposed target corridor of 3.0x to 3.5x by the end of FY/20 including estimated COVID-19 effects.

                            <bdo id="j6ob8nq0" style="display:none !important"></bdo>

                          • COVID-19 will continue to impact betway altior offer’ operations in Q4/20. betway altior offer recognizes the increasing COVID-19 case numbers, and the associated various containment measures being enacted in many of the Company’s relevant markets. Thus, the Group’s FY/20 guidance assumes no containment measures that have a significant and direct impact on the health care sector that are not appropriately compensated.

                          • <noframes id="shfa5lgw" style="display:none !important">

                            <rt id="4ccsliya" style="display:none !important"></rt>


                            1 FY/19 base: €35,409 million
                            2 Net income attributable to shareholders of betway altior offer SE & Co. KGaA
                            3 FY/19 base: €1,879 million; before special items (transaction-related expenses, revaluations of biosimilars contingent purchase price liabilities, gain related to divestitures of Care Coordination activities at FMC, expenses associated with the cost optimization program at FMC); FY/20: before special items
                            4 At LTM average exchange rates for both net debt and EBITDA; pro forma closed acquisitions/divestitures; excluding further potential acquisitions; before special items
                            For a detailed overview of special items please see the reconciliation tables on pages 17-19 in the PDF document.

                            • <col id="camdsmi0" style="display:none !important"></col><param id="czc5euhi" style="display:none !important"><fieldset id="gopbtnr2" style="display:none !important"></fieldset></param><abbr id="512kdx1c" style="display:none !important"><var id="b36wh94t" style="display:none !important"></var></abbr><rt id="c9vqo845" style="display:none !important"><h4 id="3ic6ou86" style="display:none !important"></h4><var id="55hso5j5" style="display:none !important"><samp id="g40y5l7p" style="display:none !important"></samp></var><ruby id="vwn44lx0" style="display:none !important"><h6 id="06kqjsv7" style="display:none !important"></h6><table id="ki924zrz" style="display:none !important"><table id="2dzgm7ws" style="display:none !important"></table></table></ruby></rt><select id="t9cv3uo5" style="display:none !important"><select id="j6iw2dkm" style="display:none !important"></select></select><small id="xdt859i6" style="display:none !important"><p id="oy5u8jxc" style="display:none !important"></p><tbody id="zl6d0t6o" style="display:none !important"><dt id="4baxi30e" style="display:none !important"></dt></tbody><colgroup id="nih41xia" style="display:none !important"><td id="c5n7d4ut" style="display:none !important"></td><a id="gnh7r4pq" style="display:none !important"><track id="eqp0u1g6" style="display:none !important"></track></a></colgroup><a id="xeaa55ib" style="display:none !important"><progress id="rek0iesb" style="display:none !important"></progress></a><rt id="kou8vvmo" style="display:none !important"><samp id="tqrnwxz4" style="display:none !important"></samp></rt></small><source id="aoozv2ul" style="display:none !important"><commend id="kdkzv2mn" style="display:none !important"></commend></source><dfn id="7n6puf92" style="display:none !important"><dt id="025ntbca" style="display:none !important"></dt><strike id="a3bhuqjb" style="display:none !important"><embed id="8cd9pi92" style="display:none !important"></embed></strike><dd id="6y43zu5q" style="display:none !important"><sub id="6jrmvre5" style="display:none !important"></sub></dd><em id="8hanx7o6" style="display:none !important"><h4 id="3l1n0ht5" style="display:none !important"></h4></em><h1 id="km81xoeh" style="display:none !important"><meter id="8bs1okrj" style="display:none !important"></meter><datalist id="9nio6ws3" style="display:none !important"><ul id="aqj3s2gl" style="display:none !important"></ul></datalist><b id="hby01u73" style="display:none !important"><h4 id="wrm2qacy" style="display:none !important"></h4><noframes id="moobej96" style="display:none !important"><output id="otq4xnsk" style="display:none !important"></output>


                                   

                                    1. 5% sales growth in constant currency
                                      Group sales increased by 1% (5% in constant currency) to €8,918 million (Q3/19: €8,842 million). Organic sales growth was 3%. Acquisitions/divestitures contributed net 2% to growth. Currency translation had a negative impact on sales growth of 4%. Excluding estimated COVID-19 effects1 ,Group sales growth would have been 6% to 7%, in constant currency. In Q1-3/20, Group sales increased by 3% (5% in constant currency) to €26,973 million (Q1-3/19: €26,098 million). Organic sales growth was 3%. Acquisitions/divestitures contributed net 2% to growth. Currency translation had a negative impact on sales growth of 2%. Excluding estimated COVID-19 effects1, Group sales growth would have been 7% to 8% in constant currency.

                                         

                                        1% net income2,3 growth in constant currency
                                        Group EBITDA decreased by 2% (increased by 2% in constant currency) to €1,729 million (Q3/192: €1,763 million). In Q1-3/20, Group EBITDA increased by 2% (2% in constant currency) to €5,246 million (Q1-3/192: €5,167 million).

                                          <noscrip id="wu56j9w8" style="display:none !important"></noscrip>

                                          1. Group EBIT decreased by 3% (increased by 1% in constant currency) to €1,113 million (Q3/192: €1,153 million). The missing contribution from elective procedures, volume headwinds leading to underutilized production capacities, COVID-19 related project delays at betway altior offer Vamed as well as Group-wide COVID-19 related expenses weighed on EBIT. The EBIT margin was 12.5% (Q3/192: 13.0%). In Q1-3/20, Group EBIT decreased by 1% (0% in constant currency) to €3,361 million (Q1-3/192: €3,401 million). The EBIT margin was 12.5% (Q1-3/192: 13.0%). Following higher levels of investments in recent years, betway altior offer sees higher levels of depreciation and amortization in 2020.

                                            <commend id="4j9sm1n3" style="display:none !important"></commend>

                                          2. <table id="dz3v8zqu" style="display:none !important"></table>

                                            • Group net interest before special items improved to -€154 million (Q3/19: -€171 million) mainly due to successful refinancing activities, lower interest rates as well as currency translation effects. Reported Group net interest improved to -€154 million (Q3/19: -€172 million). In Q1-3/20, Group net interest before special items improved to -€495 million (Q1-3/19: -€532 million) while reported Group net interest improved to -€503 million (Q1-3/19: -€535 million).

                                                1 For estimated COVID-19 effects in Q3/20 and Q1-3/20 please see table on page 15 in the PDF document.
                                                2 Before special items
                                                3 Net income attributable to shareholders of betway altior offer SE & Co. KGaA

                                                For a detailed overview of special items please see the reconciliation tables on pages 17-19 in the PDF document.

                                                 

                                                <dfn id="heny6zmn" style="display:none !important"></dfn><dl id="wub5nvcd" style="display:none !important"><rt id="26o8qy4l" style="display:none !important"></rt></dl><var id="5kpp9nmg" style="display:none !important"><p id="x31qq9h3" style="display:none !important"></p></var>

                                                  The Group tax rate before special items (Q3/19: 23.1%) and the reported Group tax rate (Q3/19: 21.2%) were 22.0%. In Q1-3/20, the Group tax rate before special items (Q1-3/19: 23.1%) and the reported Group tax rate (Q1-3/19: 22.4%) were 22.7%.

                                                  <tbody id="q9o7vwy4" style="display:none !important"></tbody><acronym id="33twnfl5" style="display:none !important"><dir id="vstlpcd4" style="display:none !important"></dir></acronym><figure id="unwzfu2d" style="display:none !important"><object id="vzui66k9" style="display:none !important"></object><area id="puvc8gj3" style="display:none !important"><kbd id="hkn0lpak" style="display:none !important"></kbd></area></figure><progress id="3ur92be7" style="display:none !important"><h2 id="u0fmwh16" style="display:none !important"></h2></progress><time id="i0he6tnu" style="display:none !important"><del id="680p7oqd" style="display:none !important"></del></time><nav id="fe7pzgnu" style="display:none !important"><noscrip id="zxqw7588" style="display:none !important"></noscrip><i id="5yhftal4" style="display:none !important"><table id="vdvgcrx9" style="display:none !important"></table></i><sub id="8vhhk7ef" style="display:none !important"><thead id="7hxxd49m" style="display:none !important"></thead></sub><tbody id="je85oq7t" style="display:none !important"><menu id="wgmkud3s" style="display:none !important"></menu><param id="3adxpzbu" style="display:none !important"><rp id="nt9gedbc" style="display:none !important"></rp></param><canvas id="c3qosmov" style="display:none !important"><ol id="fdy8w6oo" style="display:none !important"></ol></canvas></tbody><del id="kg5ivw09" style="display:none !important"><fieldset id="wwug9ynf" style="display:none !important"></fieldset></del></nav><dfn id="2y2t72qm" style="display:none !important"><table id="s39edr46" style="display:none !important"></table><i id="uzt2x7td" style="display:none !important"><p id="sksnx1y5" style="display:none !important"></p></i><code id="fwuau098" style="display:none !important"><ins id="422vx7ac" style="display:none !important"></ins></code><table id="xqo1k450" style="display:none !important"><ol id="3o1bn8u4" style="display:none !important"></ol></table><audio id="2drouewy" style="display:none !important"><audio id="kafreur8" style="display:none !important"></audio><datalist id="6t8k9ot9" style="display:none !important"><colgroup id="ul3b3acx" style="display:none !important"></colgroup></datalist><bdo id="7aahgdty" style="display:none !important"><embed id="nxib9dye" style="display:none !important"></embed><object id="9baldwfp" style="display:none !important"><source id="wu5nyka6" style="display:none !important"></source></object></bdo><rp id="4p5cqk91" style="display:none !important"><h1 id="9idky1ci" style="display:none !important"></h1><a id="vvvsm5qu" style="display:none !important"><kbd id="630ygak5" style="display:none !important"></kbd></a><dd id="dnzlzc5c" style="display:none !important"><sub id="u2cv9mds" style="display:none !important"></sub></dd></rp></audio><optgroup id="5tklhmvo" style="display:none !important"><select id="8e0w1np4" style="display:none !important"></select><dialog id="87oytevj" style="display:none !important"><del id="mijjgxi8" style="display:none !important"></del></dialog><var id="on5eplxg" style="display:none !important"><sup id="l0z4c4sm" style="display:none !important"></sup></var><table id="d6zfswrv" style="display:none !important"><u id="i4to7q96" style="display:none !important"></u></table><thead id="e1xq660o" style="display:none !important"><p id="8kwwlkci" style="display:none !important"></p><address id="cbodsqn6" style="display:none !important"><em id="dd8mhi35" style="display:none !important"></em></address><font id="t77j8koa" style="display:none !important"><source id="b5ufg707" style="display:none !important"></source></font><big id="e3b3is18" style="display:none !important"><embed id="icqyw76j" style="display:none !important"></embed></big></thead></optgroup></dfn>

                                                    Noncontrolling interests before special items and reported noncontrolling interests were €321 million (Q3/19: both €310 million), of which 97% were attributable to the noncontrolling interests in betway altior offer Medical Care. In Q1-3/20, noncontrolling interests before special items and reported were €913 million (Q1-3/19 before special items: €834 million; reported €826 million).

                                                          Group net income1 before special items decreased by 4% (increased by 1% in constant currency) to €427 million (Q3/19: €445 million). Excluding estimated COVID-19 effects2, net income before special items and in constant currency would have grown 1% to 5%. Reported Group net income1 was €427 million (Q3/19: €444 million). In Q1-3/20, Group net income1 before special items decreased by 5% (-4% in constant currency) to €1,302 million (Q1-3/19: €1,373 million). Excluding estimated COVID-19 effects2, net income before special items and in constant currency would have grown 2% to 6%. Reported Group net income1 was €1,297 million (Q1-3/19: €1,368 million).

                                                        1. <img id="zx3y7xrz" style="display:none !important"></img><th id="9z573ils" style="display:none !important"><i id="lgmxs1bd" style="display:none !important"></i></th>
                                                            <track id="oiooh4q3" style="display:none !important"></track><table id="96s37hyk" style="display:none !important"><colgroup id="ivd0mqxq" style="display:none !important"></colgroup></table><acronym id="k09iu2o8" style="display:none !important"><colgroup id="mxqw72d0" style="display:none !important"></colgroup><h5 id="zq5u44p0" style="display:none !important"><dfn id="nbvpsu2v" style="display:none !important"></dfn></h5></acronym>


                                                            Earnings per share1 before special items decreased by 4% (0% in constant currency) to €0.77 (Q3/19: €0.80). Reported earnings per share1 were €0.77 (Q3/19: €0.80). In Q1-3/20, earnings per share1 before special items decreased by 5% (-4% in constant currency) to €2.34 (Q1-3/19: €2.47). Reported earnings per share1 were €2.33 (Q1-3/19: €2.46).

                                                                <summary id="8a48yhr2" style="display:none !important"></summary>

                                                                 

                                                              1. <track id="cr5gl4vh" style="display:none !important"></track>

                                                                Continued investment in growth
                                                                Spending on property, plant and equipment was €521 million corresponding to 6% of sales (Q3/19: €586 million; 7% of sales). These investments served primarily for the modernization and expansion of dialysis clinics, production facilities as well as hospitals, and day clinics. Despite the COVID-19 pandemic, betway altior offer has been largely able to continue its investment programs, although there remains some uncertainty on the timing of projects for the remainder of the year. In Q1-3/20, spending on property, plant and equipment was €1,542 million corresponding to 6% of sales (Q1-3/19: €1,592 million; 6% of sales).

                                                              2. Total acquisition spending was €142 million (Q3/19: €135 million). In Q1-3/20, total acquisition spending was €651 million, mainly for the acquisition of three hospitals in Colombia by betway altior offer Helios (Q1-3/19: €2,292 million, mainly for the acquisition of NxStage by betway altior offer Medical Care).

                                                                 

                                                                1 Net income attributable to shareholders of betway altior offer SE & Co. KGaA
                                                                2 For estimated COVID-19 effects in Q3/20 and Q1-3/20 please see table on page 15 in the PDF document.
                                                                For a detailed overview of special items please see the reconciliation tables on pages 17-19 in the PDF document.

                                                                1. <bdo id="np0cthb9" style="display:none !important"></bdo><div id="3y7vrx6v" style="display:none !important"><blockquote id="3kkcm8ga" style="display:none !important"></blockquote></div>

                                                                    <noscrip id="ylq0m9ih" style="display:none !important"></noscrip>

                                                                     

                                                                  1. <kbd id="3icd2l5i" style="display:none !important"></kbd><span id="bc3a0bge" style="display:none !important"><code id="3gqm02kv" style="display:none !important"></code></span><dir id="4s5cj3sn" style="display:none !important"><fieldset id="u8pn5ba5" style="display:none !important"></fieldset><abbr id="z8tf50j7" style="display:none !important"><td id="6ijwfzw2" style="display:none !important"></td></abbr></dir><font id="kdj8pmpt" style="display:none !important"><address id="32vat0gl" style="display:none !important"></address></font>

                                                                  2. Good cash flow development
                                                                    Group operating cash flow was €1,199 million (Q3/19: €1,483 million) with a margin of 13.4% (Q3/19: 16.8%). Free cash flow before acquisitions and dividends was €682 million (Q3/19: €907 million). Given dividend payment in Q3/20 versus Q2/19, Free cash flow after acquisitions and dividends was -€185 million (Q3/19: €732 million).

                                                                      <table id="7cao76ej" style="display:none !important"></table>

                                                                      <noscrip id="1e3o61yc" style="display:none !important"></noscrip>

                                                                      <ol id="s6c8rilq" style="display:none !important"></ol><del id="fwux1mcw" style="display:none !important"><audio id="kqxbai5e" style="display:none !important"></audio></del>

                                                                      In Q1-3/20, Group operating cash flow increased to €5,159 million (Q1-3/19: €2,977 million) with a margin of 19.1% (Q1-3/19: 11.4%). The increase was largely driven by betway altior offer Medical Care due to the U.S. federal relief funding and advanced payments under the Coronavirus Aid, Relief and Economic Security Act (CARES Act) as well as by the shorter payment periods of the COVID-19 governmental compensation and reimbursement scheme for Helios Germany. Free cash flow before acquisitions and dividends was €3,593 million (Q1-3/19: €1,388 million). Free cash flow after acquisitions and dividends was €2,149 million (Q1-3/19: -€1,634 million, driven by the acquisition of NxStage by betway altior offer Medical Care).
                                                                       

                                                                        • Solid balance sheet structure
                                                                          Group total assets increased by 2% (5% in constant currency) to €68,321 million (Dec. 31, 2019: €67,006 million). Current assets increased by 10% (15% in constant currency) to €16,833 million (Dec. 31, 2019: €15,264 million), mainly driven by the increase of cash and cash equivalents. Non-current assets remained nearly unchanged (2% in constant currency) at €51,488 million (Dec. 31, 2019: €51,742 million).

                                                                          <nav id="3axo738v" style="display:none !important"></nav>
                                                                          <h5 id="r5p46gkl" style="display:none !important"></h5><commend id="9s596cxi" style="display:none !important"><td id="cyla5sdr" style="display:none !important"></td></commend><h4 id="sjrvk2iw" style="display:none !important"><small id="ft1ewd62" style="display:none !important"></small><div id="vixy7739" style="display:none !important"><i id="2afz30lc" style="display:none !important"></i></div></h4><ins id="vfw9q9dx" style="display:none !important"><dfn id="2kqrbax5" style="display:none !important"></dfn></ins>

                                                                          <h1 id="3osrm471" style="display:none !important"></h1>

                                                                          Total shareholders’ equity decreased by 1% (increased by 4% in constant currency) to €26,201 million (Dec. 31, 2019: €26,580 million). The equity ratio was 38.3% (Dec. 31, 2019: 39.7%).

                                                                          <del id="g3emmupj" style="display:none !important"></del>

                                                                            <track id="i0nrt140" style="display:none !important"></track><b id="0vhopna6" style="display:none !important"><address id="brr6ni32" style="display:none !important"></address></b><datalist id="bx0ioowo" style="display:none !important"><sub id="hfn91nnv" style="display:none !important"></sub></datalist><summary id="45naa6ea" style="display:none !important"><time id="u84mr2m9" style="display:none !important"></time><bdi id="i9c9fv27" style="display:none !important"><dialog id="67n8f2zy" style="display:none !important"></dialog></bdi><h3 id="a0m0gmq2" style="display:none !important"><label id="1hyh29w6" style="display:none !important"></label></h3></summary><abbr id="0kixw2sn" style="display:none !important"><sub id="bysi6xpm" style="display:none !important"></sub><em id="igrkvhn0" style="display:none !important"><canvas id="hwmktio4" style="display:none !important"></canvas></em><ol id="ykp3k5yo" style="display:none !important"><figure id="chucp65y" style="display:none !important"></figure><h1 id="oudj8qaj" style="display:none !important"><sub id="b1fg46sx" style="display:none !important"></sub></h1></ol><object id="bnvfpp9m" style="display:none !important"><dfn id="vupq7p2d" style="display:none !important"></dfn><object id="f5tnsk4c" style="display:none !important"><wbr id="0ggs4v99" style="display:none !important"></wbr></object><em id="gut4dc51" style="display:none !important"><h5 id="f3e8knf3" style="display:none !important"></h5></em></object></abbr>

                                                                            Group debt remained nearly unchanged (increased by 1% in constant currency) at €27,171 million (Dec. 31, 2019: € 27,258 million). Group net debt decreased by 4% (-3% in constant currency) to € 24,513 million (Dec. 31, 2019: € 25,604 million), driven by the exceptional cash flow development.

                                                                          1. <optgroup id="k19qggss" style="display:none !important"></optgroup><dl id="i06tz5pd" style="display:none !important"><q id="gooxqy8q" style="display:none !important"></q></dl><sup id="h7wrzaed" style="display:none !important"><h3 id="ta2a510k" style="display:none !important"></h3><table id="h493bkrv" style="display:none !important"><a id="80lhyuni" style="display:none !important"></a></table></sup><datalist id="oq85yao7" style="display:none !important"><ol id="8vah9xqy" style="display:none !important"></ol><i id="ar3v0hy7" style="display:none !important"><address id="wb4ur94p" style="display:none !important"></address></i><big id="gefj90yy" style="display:none !important"><rt id="72z7btqc" style="display:none !important"></rt></big></datalist><dfn id="i94fbfn0" style="display:none !important"><embed id="dq8h00t9" style="display:none !important"></embed><area id="k7z12z9s" style="display:none !important"><dir id="jtt1mdv2" style="display:none !important"></dir></area><commend id="he7yps86" style="display:none !important"><object id="97rkxjzy" style="display:none !important"></object></commend><time id="q1iifym6" style="display:none !important"><td id="azw7rqjs" style="display:none !important"></td></time></dfn>

                                                                            • As of September 30, 2020, the net debt/EBITDA ratio improved to 3.45x1,2 (Dec. 31, 2019: 3.61x1,2) driven by the exceptional cash flow development, despite COVID-19 effects weighing on EBITDA.
                                                                               

                                                                              1 At LTM average exchange rates for both net debt and EBITDA; pro forma closed acquisitions/divestitures
                                                                              2 Before special items
                                                                              For a detailed overview of special items please see the reconciliation tables on pages 17-19 in the PDF document.

                                                                              • <del id="k0llzjr5" style="display:none !important"></del>

                                                                                <address id="rgvnjd3u" style="display:none !important"></address>

                                                                                     

                                                                                    <canvas id="y325z5sv" style="display:none !important"></canvas>

                                                                                    <del id="v2798npw" style="display:none !important"></del>
                                                                                  • Business Segments
                                                                                     

                                                                                    <span id="sspi6ii8" style="display:none !important"></span>

                                                                                    1. <dfn id="uacy53oq" style="display:none !important"></dfn>

                                                                                        <wbr id="fj3u8i3g" style="display:none !important"></wbr>

                                                                                      1. betway altior offer Medical Care (Financial data according to betway altior offer Medical Care press release)
                                                                                        betway altior offer Medical Care is the world's largest provider of products and services for individuals with renal diseases. As of September 30, 2020, betway altior offer Medical Care was treating 349,167 patients in 4,073 dialysis clinics. Along with its core business, the company provides related medical services in the field of Care Coordination.

                                                                                          <dir id="zlvc64tt" style="display:none !important"></dir><span id="iiqucsv0" style="display:none !important"><pre id="4ijc2may" style="display:none !important"></pre></span><table id="ettyzg3n" style="display:none !important"><embed id="x8gt258d" style="display:none !important"></embed></table><ol id="90nebkuq" style="display:none !important"><rp id="h0ec0l5f" style="display:none !important"></rp><s id="38bybn12" style="display:none !important"><ol id="cjpigmi5" style="display:none !important"></ol></s><meter id="0bki02c6" style="display:none !important"><strike id="y861tn4p" style="display:none !important"></strike><object id="vv5jxjsx" style="display:none !important"><em id="0whll8y7" style="display:none !important"></em></object></meter></ol><meter id="y7hn25i1" style="display:none !important"><tbody id="zb5od1ph" style="display:none !important"></tbody><h2 id="vb7vgt2f" style="display:none !important"><td id="jbd1xqn6" style="display:none !important"></td></h2><figure id="9f3zv9uf" style="display:none !important"><optgroup id="b5eak5j2" style="display:none !important"></optgroup></figure><commend id="kgqouf82" style="display:none !important"><param id="y6px9cju" style="display:none !important"></param></commend></meter>

                                                                                          • Solid sales and strong earnings growth at constant currency continues in Q3
                                                                                          • Q3 development impacted by currency headwinds and expected lower reimbursement from calcimimetics
                                                                                          • Guidance for FY/20 confirmed

                                                                                           

                                                                                          Sales of betway altior offer Medical Care remained on prior year’s level (increased by 6% in constant currency) at €4,414 million (Q3/19: €4,419 million). Organic sales growth was 3%. Acquisitions/divestitures contributed net 3% to growth. In Q1-3/20, betway altior offer Medical Care increased sales by 4% (6% in constant currency) to €13,459 million (Q1-3/19: €12,897 million). Organic sales growth was 4%.

                                                                                                  There were no adjustments to reported EBIT in Q3/20 and Q1-3/20. Reported EBIT increased by 6% (11% in constant currency) to €632 million (Q3/19: €595 million). The reported EBIT margin was 14.3% (Q3/19: 13.5%). The increase in margin was driven by negative prior year earnings effects, an increase in commercial revenue and favorable cost management of pharmaceuticals, offsetting the lower reimbursement for calcimimetics, all in the North America region. EBIT on an adjusted basis increased by 2% (7% in constant currency) to €632 million (Q3/19: €620 million). The EBIT margin on an adjusted basis was 14.3% (Q3/19: 14.0%).


                                                                                                  1 Before special items
                                                                                                  2 Net income attributable to shareholders of betway altior offer Medical Care AG & Co. KGaA
                                                                                                  For a detailed overview of special items please see the reconciliation tables on pages 17-19 in the PDF document.

                                                                                                   

                                                                                                        <del id="o2xwuuji" style="display:none !important"></del><h2 id="cq59d66f" style="display:none !important"><nav id="d0n9pvlh" style="display:none !important"></nav></h2>

                                                                                                      In Q1-3/20, reported EBIT increased by 11% (12% in constant currency) to €1,843 million (Q1-3/19: €1,653 million). The reported EBIT margin was 13.7% (Q1-3/19: 12.8%). EBIT on an adjusted basis increased by 9% (9% in constant currency) to €1,843 million (Q1-3/19: €1,693 million). The EBIT margin on an adjusted basis was 13.7% (Q1-3/19: 13.1%).

                                                                                                      1. There were no adjustements to reported net income in Q3/20 and Q1-3/20. Reported net income1 grew by 6% (11% in constant currency) to €354 million (Q3/19: 333 million) and increased on an adjusted basis by 7% (11% in constant currency) to €354 million (Q3/19: €332 million). In Q1-3/20, reported net income1 grew by 15% (15% in constant currency) to €987 million (Q1-3/19: 857 million) and increased on an adjusted basis by 14% (14% in constant currency) to €987 million (Q1-3/19: €868 million).

                                                                                                          <time id="rw18mue5" style="display:none !important"></time>

                                                                                                          Operating cash flow was €746 million (Q3/19: €868 million) with a margin of 16.9% (Q3/19: 19.7%). In Q1-3/20, operating cash flow was €3,649 million (Q1-3/19: €1,796 million) with a margin of 27.1% (Q1-3/19: 13.9%). The increase was largely driven by the U.S. federal relief funding and advanced payments under the CARES Act and other COVID-19 relief, as well as working capital improvements driven by cash collections.

                                                                                                              betway altior offer Medical Care continues to expect both revenue2 and net income1 to grow at a mid to high single digit rate in 2020. These targets are inclusive of anticipated COVID-19 effects, in constant currency and exclude special items4. They are based on the adjusted results 2019, including the effects of the operations of the NxStage acquisition and the IFRS 16 implementation.

                                                                                                              For further information, please see betway altior offer Medical Care’s press release at www.freseniusmedicalcare.com.
                                                                                                               

                                                                                                              1 Net income attributable to shareholders of betway altior offer Medical Care AG & Co. KGaA
                                                                                                              2 FY/19 base: €17,477 million
                                                                                                              3 FY/19 base: €1,236 million (FY/20: before special items)
                                                                                                              4 Special items are effects that are unusual in nature and have not been foreseeable or not foreseeable in size or impact at the time of giving guidance.
                                                                                                              For a detailed overview of special items please see the reconciliation tables on pages 17-19 in the PDF document.

                                                                                                              <select id="lg072wkf" style="display:none !important"></select>

                                                                                                              <blockquote id="44t5dnlq" style="display:none !important"></blockquote>

                                                                                                               

                                                                                                                1. betway altior offer Kabi
                                                                                                                  betway altior offer Kabi offers intravenously administered generic drugs, clinical nutrition and infusion therapies for seriously and chronically ill patients in the hospital and outpatient environments. The company is also a leading supplier of medical devices and transfusion technology products. In the biosimilars business, betway altior offer Kabi develops products with a focus on oncology and autoimmune diseases.

                                                                                                                    <details id="m2nbl0cd" style="display:none !important"></details><td id="zpjl10x0" style="display:none !important"><del id="ahm34thq" style="display:none !important"></del></td><address id="rva6btxd" style="display:none !important"><figure id="5owygjjx" style="display:none !important"></figure></address>
                                                                                                                    <figure id="uo00c5g6" style="display:none !important"></figure>

                                                                                                                    <i id="it92ran9" style="display:none !important"></i>

                                                                                                                  • <colgroup id="et54hf10" style="display:none !important"></colgroup>

                                                                                                                      • In North America decreased demand given fewer elective treatments and some supply constraints due to temporary manufacturing issues outweighed extra demand for COVID-19 related products
                                                                                                                      • China recovery accelerates with elective treatments rebounding nearly to pre-pandemic levels
                                                                                                                      • Strong EBIT growth in Europe and positive development in China only partially compensates EBIT decrease in North America
                                                                                                                      • FY/20 guidance confirmed

                                                                                                                       

                                                                                                                      <dfn id="iv1mnvw8" style="display:none !important"></dfn>

                                                                                                                    1. Sales decreased by 4% (increased by 2% in constant currency) to €1,694 million (Q3/19: €1,761 million). Organic sales growth was 2%. Negative currency translation effects of 6% were mainly related to weakness of the US dollar, the Brazilian real and the Argentinian peso. Estimated COVID-19 effects had a slight negative impact on sales growth. In Q1-3/20, sales remained on prior year’s level (increased by 3% in constant currency) at €5,161 million (Q1-3/19: €5,153 million). Organic sales growth was 3%. Negative currency translation effects of 3% were mainly related to weakness of the Brazilian real and the Argentinian peso. Estimated COVID-19 effects had a slight negative impact on sales growth in Q1-3/20.

                                                                                                                            <time id="z1v60d7y" style="display:none !important"></time>

                                                                                                                            Sales in North America decreased by 10% (organic growth: -5%) to €558 million (Q3/19: €619 million). The decrease was driven by fewer elective treatments and supply constraints for certain products due to temporary manufacturing issues, which outweighed extra demand for COVID-19 related products. In Q1-3/20, sales in North America increased by 1% (organic growth: 1%) to €1,827 million (Q1-3/19: €1,815 million). Sales in Europe increased by 3% (organic growth: 5%) to €581 million (Q3/19: €564 million). In Q1-3/20, sales in Europe increased by 4% (organic growth: 5%) to €1,778 million (Q1-3/19: €1,709 million). Sales in Asia-Pacific decreased by 2% (organic growth: increased by 1%) to €399 million (Q3/19: €406 million). While China saw a solid recovery based on increasing elective procedures, other Asian markets are lagging behind. In Q1-3/20, sales in Asia-Pacific decreased by 5% (organic growth: -3%) to €1,069 million (Q1-3/19: €1,121 million).

                                                                                                                            1. Sales in Latin America/Africa decreased by 9% (organic growth increased by 17%) to €156 million (Q3/19: €172 million). In Q1-3/20, sales in Latin America/Africa decreased by 4% (organic growth increased by 17%) to €487 million (Q1-3/19: €508 million).

                                                                                                                                • EBIT before special items decreased by 9% (-4% in constant currency) to €278 million (Q3/191: €307 million) with an EBIT margin of 16.4% (Q3/191:17.4%). The decline is driven by headwinds leading to some underutilized production capacities in the US, coupled with selective supply constraints due to temporary manufacturing issues, incremental COVID-19 related expenses as well as a negative effect related to a write down of a receivable. Estimated COVID-19 effects, primarily lower share based remuneration costs given the capital markets situation, but also lower corporate costs due to travel restrictions and phasing of projects, had a moderate positive impact on EBIT growth. In Q1-3/20, EBIT before special items decreased by 7% (-5% in constant currency) to €859 million (Q1-3/191: €920 million) with an EBIT margin of 16.6% (Q1-3/191: 17.9%). Estimated COVID-19 effects had a slight positive impact on EBIT growth in Q1-3/20.

                                                                                                                                  <summary id="wtaz9mo3" style="display:none !important"></summary>

                                                                                                                                    Net income1,2 decreased by 7% (-1% in constant currency) to €189 million (Q3/19: €203 million). In Q1-3/20, net income1,2 decreased by 5% (-3% in constant currency) to €582 million (Q1-3/19: €614 million).

                                                                                                                                    <col id="alzp9ccy" style="display:none !important"></col>

                                                                                                                                        • Operating cash flow decreased to €225 million (Q3/19: €377 million) with a margin of 13.3% (Q3/19: 21.4%). After an excellent operating cash flow in Q2/20 that was marked by early cash receipts and tax payment holidays, betway altior offer Kabi saw the respective reversal in Q3/20. In Q1-3/20, operating cash flow increased by 13% to €836 million (Q1-3/19: €737 million) with a margin of 16.2% (Q1-3/19: 14.3%).

                                                                                                                                                    betway altior offer Kabi confirms its outlook including estimated COVID-19 effects and projects organic sales3 growth of 2% to 5% and an EBIT4 development of -6% to -3% in constant currency.

                                                                                                                                                        <h6 id="zkfeu8wm" style="display:none !important"></h6>
                                                                                                                                                        <strong id="o7u3hpia" style="display:none !important"></strong>

                                                                                                                                                        <progress id="iamkaup8" style="display:none !important"></progress>
                                                                                                                                                        <thead id="1puhy5g2" style="display:none !important"></thead>
                                                                                                                                                      • <rt id="h7qsytuv" style="display:none !important"></rt><u id="7wyybsts" style="display:none !important"><label id="t9d67x3b" style="display:none !important"></label></u><optgroup id="uyroy184" style="display:none !important"><code id="2z2eoocy" style="display:none !important"></code></optgroup>

                                                                                                                                                        <h6 id="f442o8kt" style="display:none !important"></h6><optgroup id="0fo017ib" style="display:none !important"><thead id="wrwkx6ge" style="display:none !important"></thead></optgroup>

                                                                                                                                                        <b id="6j9kvcp4" style="display:none !important"></b>

                                                                                                                                                          1 Before special items
                                                                                                                                                          2 Net income attributable to shareholders of betway altior offer SE & Co. KGaA
                                                                                                                                                          3 FY/19 base: €6,919 million
                                                                                                                                                          4 FY/19 base: €1,205 million, before special items, FY/20: before special items
                                                                                                                                                          For a detailed overview of special items please see the reconciliation tables on pages 17-19 in the PDF document.

                                                                                                                                                          <code id="i5djnunh" style="display:none !important"></code>

                                                                                                                                                        1.  

                                                                                                                                                          1. betway altior offer Helios
                                                                                                                                                            betway altior offer Helios is Europe's leading private hospital operator. The company comprises Helios Germany and Helios Spain (Quirónsalud). Helios Germany operates 86 hospitals, ~125 outpatient centers and 6 prevention centers. Quirónsalud operates 46 hospitals, 70 outpatient centers and around 300 occupational risk prevention centers. In addition, the company is active in Latin America with 7 hospitals and as a provider of medical diagnostics.

                                                                                                                                                          2. <dfn id="n7p3wih7" style="display:none !important"></dfn>

                                                                                                                                                          3. <map id="ot5u0bm8" style="display:none !important"></map>

                                                                                                                                                            •  

                                                                                                                                                                  <thead id="rvzsipy8" style="display:none !important"></thead><sub id="w6p1f7ka" style="display:none !important"><h5 id="mfa113d4" style="display:none !important"></h5></sub><canvas id="7twzv4u5" style="display:none !important"><bdi id="ixmwhs3a" style="display:none !important"></bdi></canvas><s id="dmm7kw53" style="display:none !important"><pre id="4hs9da49" style="display:none !important"></pre></s><progress id="ces0aq8r" style="display:none !important"><a id="ospjdd6x" style="display:none !important"></a><object id="3s7icl14" style="display:none !important"><noscrip id="n000k4ej" style="display:none !important"></noscrip></object><sup id="aim7pogh" style="display:none !important"><dd id="k7e5pd8k" style="display:none !important"></dd></sup><rt id="numxx9zd" style="display:none !important"><sup id="9fwhpuzw" style="display:none !important"></sup><map id="zinw4zr9" style="display:none !important"><dl id="9omqz1rp" style="display:none !important"></dl></map><source id="6bp49b8g" style="display:none !important"><colgroup id="rfu3uli2" style="display:none !important"></colgroup></source></rt></progress><thead id="nwrxf4xc" style="display:none !important"><colgroup id="y67rc53e" style="display:none !important"></colgroup><em id="fwulg5m7" style="display:none !important"><rp id="jixdv88k" style="display:none !important"></rp></em><li id="yioeo8ag" style="display:none !important"><noscrip id="8fauedd3" style="display:none !important"></noscrip></li><rp id="lr8f1p2i" style="display:none !important"><select id="fay79hae" style="display:none !important"></select></rp><bdo id="zs7xy9w1" style="display:none !important"><img id="3mlh9qq7" style="display:none !important"></img></bdo></thead><sup id="undr5k52" style="display:none !important"><pre id="7yetf8sw" style="display:none !important"></pre><i id="0lxw1nvo" style="display:none !important"><rt id="fjwhm2hh" style="display:none !important"></rt></i><del id="meey19fr" style="display:none !important"><audio id="syyu62ee" style="display:none !important"></audio><h5 id="f7tqwy1j" style="display:none !important"><kbd id="otc9zpey" style="display:none !important"></kbd></h5></del><object id="gwtx8643" style="display:none !important"><li id="or3x68m4" style="display:none !important"></li><span id="l8d1wj44" style="display:none !important"><em id="jdc8y440" style="display:none !important"></em></span><em id="xnrbn5lu" style="display:none !important"><label id="hgdyxj2c" style="display:none !important"></label></em></object><progress id="x5c0z8ft" style="display:none !important"><h3 id="spvi111t" style="display:none !important"></h3></progress><h5 id="3ieg6s98" style="display:none !important"><h2 id="40wwm45q" style="display:none !important"></h2><area id="ylknw7o6" style="display:none !important"><dfn id="ayy1djk1" style="display:none !important"></dfn></area><rt id="89x7bdq1" style="display:none !important"><li id="joq8wmes" style="display:none !important"></li><td id="s7dyp06o" style="display:none !important"><select id="1ej6o8pz" style="display:none !important"></select></td></rt><ins id="jb9uiisc" style="display:none !important"><colgroup id="wzdqpuq3" style="display:none !important"></colgroup><var id="fxm7w1gl" style="display:none !important"><embed id="3phfujwy" style="display:none !important"></embed></var><sub id="2gfhn7k5" style="display:none !important"><td id="d12vaswq" style="display:none !important"></td><span id="7c19y4qg" style="display:none !important"><embed id="z6h5ok47" style="display:none !important"></embed></span></sub></ins><dfn id="3kqlmyt1" style="display:none !important"><sup id="8ki0bz52" style="display:none !important"></sup></dfn></h5></sup>

                                                                                                                                                                  • Recovery of elective procedures in Germany and Spain
                                                                                                                                                                  • Helios Spain with significant growth based on catch-up effects; momentum accelerated by dynamic growth of outpatient treatments
                                                                                                                                                                  • FY/20 guidance confirmed

                                                                                                                                                                  Sales increased by 8% (8% in constant currency) to €2,400 million (Q3/19: €2,230 million). Organic growth was 6%. Acquisitions contributed 2% to sales growth. COVID-19 effects had an insignificant effect on organic sales growth. In Q1-3/20, betway altior offer Helios increased sales by 4% (5% in constant currency) to €7,181 million (Q1-3/19: €6,890 million). Organic growth was 3%. Acquisitions contributed 2% to sales growth. COVID-19 effects had a moderate negative impact on organic sales growth in Q1-3/20. betway altior offer sees a gradual recovery of elective procedures in Germany and Spain since May.

                                                                                                                                                                    • <rp id="kohg46tn" style="display:none !important"></rp>

                                                                                                                                                                      Sales of Helios Germany increased by 4% (organic growth: 4%) to €1,529 million (Q3/19: €1,474 million). In Q1-3/20, Sales of Helios Germany increased by 5% (organic growth: 5%) to €4,703 million (Q1-3/19: €4,465 million). Due to the law to ease the financial burden on hospitals, COVID-19 effects had only a slight negative impact on organic sales growth in both, Q3/20 and in Q1-3/20.

                                                                                                                                                                        <blockquote id="rmn7oy4s" style="display:none !important"></blockquote>

                                                                                                                                                                        Sales of Helios Spain increased by 15% (17% in constant currency) to €870 million (Q3/19: €757 million). Organic growth of 10% was driven by a strong recovery of elective procedures and additionally fueled by increased outpatient treatments. Thus COVID-19 effects had a slight positive impact on organic sales growth. The hospital acquisitions in Colombia contributed 7% to sales growth. In Q1-3/20, sales of Helios Spain increased by 2% (3% in constant currency) to €2,476 million (Q1-3/19: €2,425 million). Organic growth was -2%. Acquisitions contributed 5% to sales growth. COVID-19 effects had a significant negative impact on organic sales growth in Q1-3/20.

                                                                                                                                                                            EBIT of betway altior offer Helios increased by 20% (20% in constant currency) to €225 million (Q3/19: €187 million) with an EBIT margin of 9.4% (Q3/19: 8.4%). COVID-19 effects had a significant positive effect on EBIT growth. In Q1-3/20, EBIT of betway altior offer Helios decreased by 5% (-5% in constant currency) to €697 million (Q1-3/19: €731 million) with an EBIT margin of 9.7% (Q1-3/19: 10.6%). COVID-19 effects had a significant negative impact on EBIT growth in Q1-3/20.

                                                                                                                                                                          • EBIT of Helios Germany increased by 2% to €133 million (Q3/19: €131 million) with an EBIT margin of 8.7% (Q3/19: 8.9%). In Q1-3/20, EBIT of Helios Germany increased by 3% to €445 million (Q1-3/19: €434 million) with an EBIT margin of 9.5% (Q1-3/19: 9.7%). Due to the law to ease the financial burden on hospitals, COVID-19 effects had only a slight negative impact on EBIT growth in both Q3/20 and Q1-3/20.

                                                                                                                                                                          • <noscrip id="i9c5fww4" style="display:none !important"></noscrip>

                                                                                                                                                                            EBIT of Helios Spain increased by 61% (63% in constant currency) to €95 million (Q3/19: €59 million) with an EBIT margin of 10.9% (Q3/19: 7.8%). The growth is driven by a recovery of elective procedures following the government-ordered postponement of planned surgical procedures in Q2, where medically justifiable. Thus, COVID-19 effects had a very significant positive effect on EBIT growth in Q3/20. In Q1-3/20, EBIT of Helios Spain decreased by 15% (-15% in constant currency) to €261 million (Q1-3/19: €307 million) with an EBIT margin of 10.5% (Q1-3/19: 12.7%). COVID-19 effects had a significant negative impact on EBIT growth in Q1-3/20 with missing or delayed elective procedures and higher expenses amidst the comprehensive efforts to combat the pandemic.

                                                                                                                                                                            Net income1 increased by 27% to €142 million (Q3/19: €112 million). In Q1-3/20, net income1 decreased by 6% to €441 million (Q1-3/19: €467 million).

                                                                                                                                                                            <noframes id="0tr43pc4" style="display:none !important">

                                                                                                                                                                            Operating cash flow increased to €275 million (Q3/19: €196 million) with a margin of 11.5% (Q3/19: 8.8%), driven by phasing of payments under the German law to ease the financial burden on hospitals. In Q1-3/20, operating cash flow increased to €715 million (Q1-3/19: €507 million) with a margin of 10.0% (Q1-3/19: 7.4%).

                                                                                                                                                                          • 
                                                                                                                                                                            
                                                                                                                                                                            

                                                                                                                                                                            betway altior offer Helios confirms its outlook including estimated COVID-19 effects and expects organic sales2 growth of 1% to 4% and EBIT3 broadly stable over FY/19 in constant currency.

                                                                                                                                                                                1 Net income attributable to shareholders of betway altior offer SE & Co. KGaA
                                                                                                                                                                                2 FY/19 base: €9,234 million
                                                                                                                                                                                3 FY/19 base: €1,025 million

                                                                                                                                                                                 

                                                                                                                                                                                betway altior offer Vamed
                                                                                                                                                                                betway altior offer Vamed manages projects and provides services for hospitals and other health care facilities worldwide and is a leading post-acute care provider in Central Europe. The portfolio ranges along the entire value chain: from project development, planning, and turnkey construction, via maintenance and technical management to total operational management.

                                                                                                                                                                                <dt id="e5ye529s" style="display:none !important"></dt><p id="uffjb1ae" style="display:none !important"><output id="62gtim1y" style="display:none !important"></output></p>

                                                                                                                                                                                • <q id="5s402abh" style="display:none !important"></q>

                                                                                                                                                                                  • Significant negative COVID-19 impact continued through Q3
                                                                                                                                                                                  •  Projects and project order intake continued to be marked by delays, cancellations and global supply chain restraints due to COVID-19
                                                                                                                                                                                  •  Lower capacities in the post-acute-care business due to health authority induced capacity restrictions and postponements of elective surgeries; less demand for rehabilitation treatments; high-end technical service remained robust
                                                                                                                                                                                  •  FY/20 EBIT guidance revised


                                                                                                                                                                                  Sales of betway altior offer Vamed decreased by 8% (-8% in constant currency) to €517 million (Q3/19: €562 million). Organic sales growth was -10%. Acquisitions contributed 2% to growth. Estimated COVID-19 effects had a significant negative impact on growth in Q3/20. In Q1-3/20, betway altior offer Vamed increased sales by 1% (1% in constant currency) to €1,491 million (Q1-3/19: €1,469 million). Organic sales growth was -1%. Acquisitions contributed 2% to growth. Estimated COVID-19 effects had a significant negative impact on sales growth in Q1-3/20.

                                                                                                                                                                                    <img id="mz0pxjt9" style="display:none !important"></img>
                                                                                                                                                                                • Sales in the service business increased by 8% to €377 million (Q3/19: €349 million).

                                                                                                                                                                                      <del id="2s7sg4c0" style="display:none !important"></del><dt id="o25o1j2x" style="display:none !important"><label id="f41o9js2" style="display:none !important"></label></dt>

                                                                                                                                                                                      Sales in the project business decreased by 34% to €140 million (Q3/19: €213 million), driven by postponements and cancellations of projects. In Q1-3/20, sales in the service business grew by 4% to €1,063 million (Q1-3/19: €1,025 million). Sales in the project business decreased by 4% to €428 million (Q1-3/19: €444 million).

                                                                                                                                                                                        EBIT decreased by 133% (-133% in constant currency) to -€11 million (Q3/19: €33 million) with an EBIT margin of -2.1% (Q3/19: 5.9%). Estimated COVID-19 effects had a very significant negative impact on EBIT. Capacities in the post-acute care clinics were left empty given a generally lower intake of elective surgery patients from acute-care hospitals as well as authority-instigated restrictions or even closures of individual facilities. In the project business, project delays triggered incremental expenses. In Q1-3/20, EBIT decreased by 115% (-115% in constant currency) to -€10 million (Q1-3/19: €67 million) with an EBIT margin of -0.7% (Q1-3/19: 4.6%). Estimated COVID-19 effects had a very significant negative impact on EBIT in Q1-3/20.

                                                                                                                                                                                      • <h2 id="8tqwp82h" style="display:none !important"></h2>

                                                                                                                                                                                      • Net income1 decreased to -€15 million (Q3/19: €21 million). In Q1-3/20, net income1 decreased to -€23 million (Q1-3/19: €39 million).

                                                                                                                                                                                              Order intake was €188 million in Q3/20 (Q3/19: €240 million) and €362 million in Q1-3/20 (Q1-3/19: €738 million). As of September 30, 2020, order backlog was at €2,786 million (December 31, 2019: €2,865 million). Order intake and order backlog were marked by COVID-19 related cancellations and project delays.

                                                                                                                                                                                                  • Operating cash flow decreased to -€4 million (Q3/19: €33 million) with a margin of -0.8% (Q3/19: 5.9%), driven by delayed payments in the project business, partially offset by minor compensation payments from governmental authorities related to the post-acute care business. In Q1-3/20, operating cash flow increased to €4 million (Q1-3/19: -€17 million) with a margin of 0.3% (Q1-3/19: -1.2%).

                                                                                                                                                                                                    <details id="a66smk90" style="display:none !important"></details>

                                                                                                                                                                                                    <s id="2t2s9vwe" style="display:none !important"></s>

                                                                                                                                                                                                    betway altior offer Vamed confirms its sales outlook for FY/20 and expects an organic sales2 decline of ~10%. Ongoing significant negative Covid-19 effects are expected to weigh on EBIT in Q4/20. While betway altior offer Vamed continues to project a positive EBIT3 amount for FY/20, the constant currency decline versus FY/19 is now expected to exceed the former outlook of ~50%. Both sales and EBIT outlook include estimated COVID-19 effects.


                                                                                                                                                                                                    Increased number of employees
                                                                                                                                                                                                    As of September 30, 2020, the number of employees was 309,114 (December 31, 2019: 294,134).
                                                                                                                                                                                                     

                                                                                                                                                                                                    1 Net income attributable to shareholders of VAMED AG
                                                                                                                                                                                                    2 FY/19 base: €2,206 million
                                                                                                                                                                                                    3 FY/19 base: €134 million

                                                                                                                                                                                                  • <code id="9d91fcax" style="display:none !important"></code><optgroup id="iwy1ea4g" style="display:none !important"><wbr id="l0am5uxl" style="display:none !important"></wbr></optgroup><mark id="ra9c2dul" style="display:none !important"><del id="8no80i7e" style="display:none !important"></del></mark>

                                                                                                                                                                                                     

                                                                                                                                                                                                      <fieldset id="270nfsz4" style="display:none !important"></fieldset>

                                                                                                                                                                                                        Conference Call
                                                                                                                                                                                                        As part of the publication of the results for Q3/2020, a conference call will be held on October 29, 2020 at 1:30 p.m. CET (8:30 a.m. EDT). You are cordially invited to follow the conference call in a live broadcast over the Internet at flowerjewellery.in/media-calendar. Following the call, a replay will be available on our website.

                                                                                                                                                                                                           

                                                                                                                                                                                                        • <acronym id="u29sideo" style="display:none !important"></acronym>
                                                                                                                                                                                                          1. <tt id="ec4v8l22" style="display:none !important"></tt>

                                                                                                                                                                                                          2. For additional information on the performance indicators used please refer to our website flowerjewellery.in/alternative-performance-measures.